Drug Trial Radar · NCT06932536
The Pharmacokinetics (PK), Safety, Tolerability of SR750 (Formulation F1) in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Apr 28, 2025
Primary completion
Jul 7, 2025
Study completion Jul 7, 2025
Sponsor
- Lead sponsor
- Shanghai SIMR Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled phase I bridging study to evaluate the PK, safety and tolerability of SR750 (formulation F1) in Chinese healthy subjects.
Conditions
- Healthy
Interventions
SR750 tabletDrug
Ascending single (30-100 mg) and multiple (30-60 mg twice daily \[b.i.d.\]) doses of SR750 orally
PlaceboDrug
Ascending single and multiple doses of placebo orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: Up to 48 hours post-dose
- TmaxTime frame: Up to 48 hours post-dose
- AUCTime frame: Up to 48 hours post-dose
- CL/FTime frame: Up to 48 hours post-dose
- t1/2Time frame: Up to 48 hours post-dose
- RacTime frame: Up to 48 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Clinical Research Center Phase I Clinical Research Unit (SCRC-PCRU)
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.